Engineered immune cells take on recurrent brain tumors in early trial
NCT ID NCT06964737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new type of immunotherapy called anti-GARP CAR T-cell therapy for people with recurrent high-grade gliomas (aggressive brain tumors). Researchers will take a patient's own immune cells, modify them in the lab to target a protein called GARP found on tumor cells, and then infuse them back into the brain. The main goals are to find the safest dose and to see if the treatment is tolerable, with 30 participants enrolled at a single medical center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-GARP CAR T-cells
What this could lead to
If this works, it could point toward a new treatment option for recurrent high-grade gliomas, a type of brain cancer with few effective therapies.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, not yet on effectiveness. The therapy may not shrink tumors or improve survival, and there are risks of serious side effects from the CAR T-cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WHO GRADE 4 GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact